Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13296776 | 0.84 | CYP11B2 (0.51) | CYP11B1CYP11B2GRM5CYP1A1CYP1B1 | |
| SCHEMBL19250964 | 0.81 | CYP11B1 (0.41) | CYP11B1CYP11B2KCNH2KDM1AMAOA | |
| SCHEMBL91481 | 0.81 | CYP11B1 (0.46) | CYP11B1CYP11B2KCNH2KDM1AMAOA | |
| SCHEMBL27704092 | 0.80 | CYP11B2 (0.43) | CYP11B1CYP11B2KCNH2KDM1AMAOA | |
| SCHEMBL22307597 | 0.80 | CYP11B1 (0.43) | CYP11B1CYP11B2GRM5GRIN1GRIN2B | |
| SCHEMBL1770087 | 0.79 | CYP11B1 (0.57) | CYP11B1CYP11B2KCNH2KDM1AMAOA | |
| SCHEMBL7674254 | 0.79 | CYP11B1 (0.45) | CYP11B1CYP11B2KCNH2KDM1AMAOA | |
| SCHEMBL22774749 | 0.79 | CYP11B1 (0.45) | CYP11B1CYP11B2KCNH2KDM1AMAOA | |
| SCHEMBL2681872 | 0.79 | CYP11B1 (0.45) | CYP11B1CYP11B2KCNH2KDM1AMAOA | |
| SCHEMBL30240891 | 0.79 | CYP11B1 (0.45) | CYP11B1CYP11B2KCNH2KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929188-A1 | PD-L1 ANTAGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2021-12-29 | — | — | EP | disclosed |
| US-10479802-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180170883-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2018-06-21 | — | — | US | disclosed |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2017-08-17 | — | — | US | disclosed |
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479802-B2 | Probes for imaging huntingtin protein | HTT, HYPK, FABP7 | CYP11B1 4010/4885CYP11B2 4299/4885KCNH2 4030/4885 |
| US-20180170883-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | CYP11B1 3010/4885CYP11B2 2870/4885KCNH2 4676/4885 |
| US-20170233352-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | CYP11B1 3351/4885CYP11B2 3155/4885KCNH2 4547/4885 |
| US-20170283436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, FABP7 | CYP11B1 4010/4885CYP11B2 4299/4885KCNH2 4030/4885 |
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | CYP11B1 43/4885CYP11B2 48/4885KCNH2 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.